Ertugliflozin CV Outcomes in T2D Population Are Similar to Placebo

September 23, 2020 09:00pm

In patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease, results from a multicenter, double-blind trial show that treatment with ertugliflozin is noninferior to placebo with respect to major adverse cardiovascular events.

Employers Increasing Virtual, Behavioral Health Coverage Amid Pandemic
TKI Leads to Superior Outcomes in ALL With an ABL-Class Fusion, Study Says
Review Updates Mechanisms Underlying Proteasome Inhibitor Resistance in MM
Phase 3 Trial Results Highlight Cemiplimab’s Potential in NSCLC
New content coming soon, please check back later.